Everything below concerns lyophilization. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-12-17. Numbers and descriptions here follow the published literature rather than marketing material.
Tirzepatide is a synthetic linear peptide of 39 amino acids that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Its sequence derives from native GIP but incorporates non-natural residues and a C20 fatty diacid moiety linked to a lysine side chain. The lipophilic chain promotes albumin binding, which slows renal clearance and extends circulation time. The unmodified peptide has a molecular formula of C225H348N48O68 and a molecular mass near 4,813 daltons.
Receptor activation by tirzepatide raises intracellular cyclic AMP through Gs-coupled signalling at both targets. At the GLP-1 receptor the downstream effect includes glucose-dependent insulin release, suppressed glucagon secretion, delayed gastric emptying, and reduced appetite signalling in the hypothalamus. GIP receptor engagement adds insulinotropic activity and appears to influence lipid handling in adipose tissue. Because both receptors are stimulated at the same time, the pharmacological profile differs from that of selective GLP-1 receptor agonists, and the relative contribution of each arm remains an area of active investigation.
Clinical development proceeded through large phase 3 programmes in type 2 diabetes and in obesity or overweight with at least one weight-related comorbidity. Regulatory approvals followed in several jurisdictions for both indications. Weekly subcutaneous dosing reflects an elimination half-life of roughly five days. Open questions include the durability of metabolic effects after treatment stops, long-term cardiovascular and hepatic outcomes beyond completed trials, and whether the dual mechanism confers benefits independent of total receptor occupancy. Published literature continues to expand on these points. Substantial uncertainty remains about interindividual variability in response.
Characterization of the peptide relies on reversed-phase high-performance liquid chromatography for purity and related-substance profiling, with ultraviolet detection near 214 nanometers. Mass spectrometry confirms molecular mass and reveals modifications such as oxidation or deamidation. Peptide mapping after enzymatic digestion verifies the amino acid sequence, while amino acid analysis supplies compositional data. Circular dichroism and infrared spectroscopy are used to assess secondary structure, particularly the alpha-helical content that influences aggregation behavior in solution.
Common degradation routes include hydrolysis of labile amide bonds, deamidation of asparagine and glutamine residues, oxidation of methionine and tryptophan, and non-covalent aggregation. Aggregates can form during freeze-thaw cycling, at elevated pH, or when peptide concentration is high. Each route produces characteristic chromatographic or mass shifts that are tracked during stability studies. Whether a given minor impurity alters biological activity is often an open question, and specification limits are typically set on identity and purity rather than on functional data for trace species.
Lyophilized material is generally held at -20 degrees Celsius or lower, desiccated and protected from light, where it remains stable for extended periods. Reconstituted or ready-to-use solution is usually kept at 2 to 8 degrees Celsius with minimal agitation. Repeated freeze-thaw cycles should be avoided because they promote aggregation and reduce the soluble monomer fraction. Shipment of frozen solid commonly uses dry ice, while refrigerated liquid moves with validated cold packs. Stability beyond documented periods is not established.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Unmodified peptide backbone |
| Molecular mass | approx. 4,813 Da | 39-residue linear chain |
| Receptor targets | GIP and GLP-1 | Dual agonist activity |
| Route | Subcutaneous injection | Weekly administration interval |
| Elimination half-life | approx. 5 days | Supports weekly dosing schedule |
Recommended storage for reference material is a freezer at approximately -20 degrees Celsius, protected from light and moisture. Commercial injectable presentations are stored refrigerated between 2 and 8 degrees Celsius and must not be frozen. Product labelling generally permits a limited period at controlled room temperature once dispensed, with the exact window depending on the presentation. Repeated temperature cycling is avoided because it can promote aggregation or deamidation of the peptide chain.
Identity and purity are assessed by reversed-phase high-performance liquid chromatography, with mass confirmation by electrospray ionisation mass spectrometry. Peptide mapping after enzymatic digestion verifies the primary sequence. Size-exclusion chromatography quantifies aggregates, while circular dichroism provides a secondary-structure fingerprint. Bioanalytical quantification in plasma uses immunoassay or LC-MS/MS. Reported purity for research-grade lots is commonly 95 percent or higher, and residual water content is checked by Karl Fischer titration.
Tirzepatide is a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual agonist profile distinguishes it from earlier incretin-based compounds that act on a single receptor. The molecule was engineered from the native GIP sequence and carries several non-natural residues that slow enzymatic breakdown. Researchers designed it to combine the insulinotropic effects of GIP signaling with the appetite and gastric-emptying effects associated with GLP-1 activation.
Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.
The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.
It appears that these effects are sequence-specific; as in most cases, if a Morpholino is associated with non-target effects, the 4-base mismatch Morpholino will not trigger these effects. A cause for concern in the use of Morpholinos is the potential for "off-target" effects. Whether an observed morphant phenotype is due to the intended knockdown or an interaction with an off-target RNA can often be addressed in embryos by running another experiment to confirm that the observed morphant phenotype results from the knockdown of the expected target. This can be done by recapitulating the morphant phenotype with a second, non-overlapping Morpholino targeting the same mRNA, by confirmation of the observed phenotypes by comparing with a mutant strain (though compensation will obscure a phenotype in some mutants), by testing the Morpholino in a null mutant background to detect additional phenotypic changes or by dominant-negative methods. As mentioned above, rescue of observed phenotypes by coinjecting a rescue mRNA is, when feasible, a reliable test of specificity of a Morpholino.
The main secondary aspect of the Discipline is that the avout are allowed to own only their "bolt, chord, and sphere". These objects are made with "newmatter" (matter made with a modified atomic structure to be more versatile), and can be made to alter their shape, texture and other physical properties without the use of tools or other outside technologies. The bolt is a length of newmatter fabric and is used as clothing; the chord is a newmatter rope used to secure the bolt; and the sphere is a newmatter balloon of adjustable size, shape and hardness, and serves as a multipurpose tool. There are several restrictions governing, for example, the use of "sequencing" (genetic engineering), "syntactic devices" (computers), or other "praxis" (technology). Due to the restrictions, avout can only work on an entirely theoretical basis de jure.
==== Service and development ==== Education Committee Higher Education and Scientific Research Committee Health Committee Agriculture and Food Security Committee Energy Committee Transport and Navigation Committee Tourism Committee Culture Committee Heritage and Cultural Diversity Committee
Sources: en.wikipedia.org
Medical museums provided examples in comparative anatomy, and were often used in teaching. Ignaz Semmelweis investigated puerperal fever and he discovered how it was caused. He noticed that the frequently fatal fever occurred more often in mothers examined by medical students than by midwives. The students went from the dissecting room to the hospital ward and examined women in childbirth. Semmelweis showed that when the trainees washed their hands in chlorinated lime before each clinical examination, the incidence of puerperal fever among the mothers could be reduced dramatically.
Analogues of MDMA include amphetamine, methamphetamine, homopiperonylamine (MDPEA), homarylamine (MDMPEA), lophophine (MMDPEA), MDA, MMDA, MMDA-2, DMMDA, DMMDA-2, MDEA, MDOH, MDMOH (FLEA), N-t-BOC-MDMA, methylone (MDMC), MBDB, 5-MAPB, 6-MAPB, 5-MAPBT, 6-MAPBT, SDMA, ODMA, SeDMA, TDMA, MDAI, and MDAT, among many others. Deuterated analogues of MDMA such as d2-MDMA have been described as well.
=== Degradation === Under extreme alkaline conditions, bronopol decomposes in aqueous solution and very low levels of formaldehyde are produced. Liberated formaldehyde is not responsible for the biological activity associated with bronopol. Other decomposition products detected after bronopol breakdown are bromide ion, nitrite ion, bromonitroethanol and 2-hydroxymethyl-2-nitropropane-1,3-diol.
Mirzayanov provided the first description of these agents. Dispersed in an ultra-fine powder instead of a gas or a vapour, they have unique qualities. A binary agent was then created that would mimic the same properties but would either be manufactured using materials which are not controlled substances under the CWC, or be undetectable by treaty regime inspections. The most potent compounds from this family, Novichok-5 and Novichok-7, are supposedly around five to eight times more potent than VX. The "Novichok" designation refers to the binary form of the agent, with the final compound being referred to by its code number (e.g. A-232). The first Novichok series compound was in fact the binary form of a known V-series nerve agent, VR, while the later Novichok agents are the binary forms of compounds such as A-232 and A-234.
Sources: en.wikipedia.org
=== September === 1 September Kelly Ana Morey, novelist and poet (born 1968) Peter Truscott, cricketer (Canterbury, Wellington, national team) (born 1941). 2 September – David H. Clark, astrophysicist (Rutherford Appleton Laboratory) and science administrator (SERC, EPSRC). 4 September – Maxine Arnold, local politician, Porirua City Councillor (1974–1992), Wellington Regional Councillor (1980–1995), first women elected to a licensing trust (1968) (born 1928). 6 September – Dame Pat Harrison, educationalist and local politician, principal of Queen's High School, Dunedin (1975–1994), University of Otago council member (1983–1994), Otago Regional Councillor (born 1932). 7 September Robin Chadwick, actor (Julius Caesar, The Brothers) (born 1939). John Irwin, psychologist (University of Auckland) (born 1934). 8 September – Tom Phillips, fugitive father who disappeared with his three children between 2021 and 2025. 9 September David Buckingham, physical chemist (Australian National University, University of Otago), Fellow of the Royal Society of New Zealand (since 1980) (born 1936). Charlie Cotton, basketball player (national team) (born 1943). 10 September – Stan Martin, rugby league player (Richmond Rovers) and coach (Whitehaven, Cook Islands, women's national team) (born 1953). 11 September Randall Morton, otolaryngologist (University of Auckland) (born 1947). Graham Young, educator, principal of Tauranga Boys' College (1985–2008).
Formylglycine-generating enzyme (FGE), located at 3p26.1 in humans, is the name for an enzyme present in the endoplasmic reticulum that catalyzes the conversion of cysteine to formylglycine (fGly). There are two main classes of FGE, aerobic and anaerobic. FGE activates sulfatases, which are essential for the degradation of sulfate esters. The catalytic activity of sulfatases is dependent upon a formylglycine (sometimes called oxoalanine) residue in the active site.
Historians have generally defined the party as conservative and wanting to maintain white Rhodesian interests by staunchly opposing majority rule, which the RF argued would lead to a collapse in economic development, law and order, and the emergence of a communist regime in Rhodesia. The party also encouraged immigration of whites from other African former colonies to Rhodesia. The RF maintained an all-white membership and wanted to continue the provision of separate amenities for different races in education and public services; thusly, the party was often characterised as racist both within Rhodesia and abroad. Ian Smith and the RF claimed that they based their policies, ideas, and democratic principles on meritocratic ideals and "not on colour or nationalism", stating that these policies and what he called "separate economic advancement" would ultimately result in an "equal partnership between black and white" as an alternative to majority rule. The Rhodesian Front was more moderate than the National Party, and never de jure disenfranchised non-white voters in their entirety and did not introduce apartheid-style legislation governing interpersonal relationships: marriage and relationships between whites and non-whites were possible and legal, albeit uncommon.
Sources: en.wikipedia.org
It is a dual GIP and GLP-1 receptor agonist, frequently grouped with incretin-based peptide therapeutics. It is a peptide rather than a small molecule and is given by subcutaneous injection.
Selective agents engage only the GLP-1 receptor, whereas tirzepatide activates GIP and GLP-1 receptors simultaneously. This difference in receptor coverage is the principal pharmacological distinction emphasised in comparative reviews.
Downstream signalling is partly characterised, but the quantitative contribution of GIP versus GLP-1 receptor activation to metabolic outcomes is not settled. Review articles commonly flag this as an unresolved question rather than a settled finding.
Reversed-phase high-performance liquid chromatography is the standard approach, separating the main peak from related impurities. Ultraviolet detection near 214 nanometers captures the peptide backbone. Mass spectrometry is then used alongside chromatography to confirm identity and detect covalent modifications.